Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferonα2a and tamoxifen in metastatic melanoma

M. R. Sertoli, P. Queirolo, E. Bajetta, M. DelVecchio, G. Comella, L. Barduagni, M. G. Bernengo, S. Vecchio, D. Criscuolo, R. Bufalino, A. Morabito, N. Cascinelli

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to evaluate the toxicity and efficacy of a monochemotherapy regimen of dacarbazine (DTIC), tamoxifen, interferon-α2a and interleukin-2 (IL-2) and two polychemotherapy regimens of cisplatin, DTIC, vindesine, tamoxifen, interferon-α2a with or without IL-2 in patients with metastatic melanoma. Consecutive patients with metastatic melanoma were enrolled in this trial and were randomized to arm A, consisting of DTIC 800 mg/m 2 every 21 days, IL-2 9 MIU subcutaneously days 1-5 and 8-12, arm B, consisting of cisplatin 30 mg/m 2 days 1-3, DTIC 250 mg/m 2 days 1-3 and vindesine 2.5 mg/m 2 day 1 every 28 days (CVD), or arm C, consisting of CVD plus IL-2 6 MIU days 1-5 and 8-12 every 28 days. In all three arms interferon 3 MU subcutaneously three times a week and tamoxifen 20 mg orally were given throughout. Ninety-two patients were included in this study. Patient characteristics in the three groups were well balanced. The three regimens were delivered on an outpatient basis without major toxicity. The toxicities that did occur consisted primarily of flu-like symptoms in the IL-2 arms (A and C) and haematological toxicities in the CVD arms (B and C). No grade IV toxicities were encountered and no treatment-related deaths occurred. The total response rate was 13% in arm A, 35% in arm B and 37% in arm C. The median duration of response was 6 months and the median survival was 11 months. According to this phase II randomized trial polychemoimmunotherapy with CVD has an objective response rate of 35-36%, while monochemoimmunotherapy with DTIC has a response rate of 13%.

Original languageEnglish
Pages (from-to)503-509
Number of pages7
JournalMelanoma Research
Volume9
Issue number5
Publication statusPublished - 1999

Keywords

  • Chemoimmunotherapy
  • Metastatic melanoma
  • Phase II study

ASJC Scopus subject areas

  • Cancer Research
  • Dermatology

Fingerprint Dive into the research topics of 'Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferonα2a and tamoxifen in metastatic melanoma'. Together they form a unique fingerprint.

Cite this